EUVIMEDObjevte EUVIMED
Open access · CC BY-NC-ND 4.0

Efficacy and tolerance of oral versus parenteral cyanocobalamin supplement in hypocobalaminaemic dogs with chronic enteropathy: a controlled randomised open‐label trial

C Dor iD, S Nixon, S Salavati Schmitz iD, J Bazelle, P Černá, S Kilpatrick, N D Harvey, M Dunning

Journal of Small Animal Practice · 2024

DOI: 10.1111/jsap.13705 ↗

At a glance

Journal article in Journal of Small Animal Practice, 2024. Written by C Dor and 7 co-authors. Institution: Department of Veterinary Medicine and Science, University of Nottingham, Nottingham, UK. Major MEDLINE topics: Dog Diseases, Vitamin B 12, Vitamin B 12 Deficiency. Cited 3 times so far (Crossref); 39 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: ADM Protexin.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Objectives

Determine comparative tolerance of daily oral and weekly parenteral cobalamin supplementation, in hypocobalaminaemic dogs with chronic enteropathy. Determine whether oral is as effective as parenteral supplementation at achieving eucobalaminaemia, in hypocobalaminaemic dogs with protein‐losing enteropathy, severe hypocobalaminaemia or high canine inflammatory bowel disease activity index at inclusion. Materials and Methods Thirty‐seven client‐owned dogs with hypocobalaminaemia and clinical signs of chronic enteropathy were prospectively enrolled in three UK referral centres. Dogs were randomly allocated to daily oral for 12 weeks or weekly parenteral cobalamin supplementation for 6 weeks and one additional dose 4 weeks later. Serum cobalamin, body condition score, canine inflammatory bowel disease activity index and bodyweight were assessed at inclusion, weeks 7 and 13. Serum methylmalonic acid concentration was evaluated at inclusion and at week 13. Owners completed treatment adherence, palatability, tolerance and satisfaction questionnaires at week 13.

Results

Nineteen dogs completed the study. All dogs orally supplemented achieved normal or increased cobalaminaemia at weeks 7 and 13. There was no statistical difference in cobalamin concentration at week 13 in dogs treated with oral or parenteral supplementation, regardless of presence of protein‐losing enteropathy, severity of hypocobalaminaemia or canine inflammatory bowel disease activity index at inclusion. Serum methylmalonic acid concentration was not significantly different between oral and parenteral groups, neither were treatment adherence, satisfaction, and tolerance scores at week 13. Clinical Significance Oral is as effective and as well‐tolerated as parenteral cobalamin supplementation in hypocobalaminaemic dogs with chronic enteropathy and severe clinical or biochemical phenotypes, and should be considered as a suitable treatment option regardless of disease severity.

Subjects

MeSH terms (MEDLINE)

Dog DiseasesVitamin B 12Vitamin B 12 DeficiencyAnimalsDogsFemaleMaleAdministration, OralChronic DiseaseInflammatory Bowel DiseasesProspective StudiesProtein-Losing EnteropathiesTreatment Outcome

Substances

Vitamin B 12

Authors and institutions

  • Department of Veterinary Medicine and Science, University of Nottingham, Nottingham, UK.
  • ADM Protexin Ltd, Lopen Head, Somerset, UK.
  • The Royal (Dick) School of Veterinary Studies and the Roslin Institute, The Hospital for Small Animals, University of Edinburgh, Edinburgh, UK.
  • Davies Veterinary Specialists, Manor Farm Business Park, Hitchin, Hertfordshire, UK.
  • Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA.
  • Idexx Laboratories, Grange House, Sandbeck Way, Wetherby, West Yorkshire, UK.

ORCID profiles: C Dor, S Salavati Schmitz

Funding

  • ADM Protexin

Cite

APA

Dor, C., Nixon, S., Salavati Schmitz, S., Bazelle, J., Černá, P., Kilpatrick, S., Harvey, N. D., & Dunning, M. (2024). Efficacy and tolerance of oral versus parenteral cyanocobalamin supplement in hypocobalaminaemic dogs with chronic enteropathy: a controlled randomised open‐label trial. Journal of Small Animal Practice. https://doi.org/10.1111/jsap.13705

Vancouver

Dor C, Nixon S, Salavati Schmitz S, Bazelle J, Černá P, Kilpatrick S, et al. Efficacy and tolerance of oral versus parenteral cyanocobalamin supplement in hypocobalaminaemic dogs with chronic enteropathy: a controlled randomised open‐label trial. Journal of Small Animal Practice. 2024. doi:10.1111/jsap.13705

BibTeX
@article{Dor2024,
  author = {Dor, C and Nixon, S and Salavati Schmitz, S and Bazelle, J and Černá, P and Kilpatrick, S and Harvey, N D and Dunning, M},
  title = {Efficacy and tolerance of oral versus parenteral cyanocobalamin supplement in hypocobalaminaemic dogs with chronic enteropathy: a controlled randomised open‐label trial},
  journal = {Journal of Small Animal Practice},
  year = {2024},
  doi = {10.1111/jsap.13705}
}
Start for free →